- Aurinia Pharmaceuticals recently entered into a settlement with Teva Pharmaceuticals resolving U.S. patent litigation over Teva’s proposed generic 7.9 mg voclosporin capsules, with Teva agreeing that Aurinia’s patents, expiring in December 2037, are valid, enforceable, and would be infringed by U.S. sales of its generic.
- The agreement, which restricts Teva from launching its generic voclosporin in the U.S. before December 7, 2036 (subject to contingencies and FDA approval), materially clarifies Aurinia’s timeline for potential generic competition while related lawsuits against several other generic challengers continue.
- We’ll now examine how this clarified generic entry date for voclosporin could influence Aurinia’s existing investment narrative around intellectual property protection.
The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.
Aurinia Pharmaceuticals Investment Narrative Recap
To own Aurinia today, you need to believe LUPKYNIS can support the business as its core asset while the pipeline and cash generation mature. The Teva settlement materially reduces near term generic risk for voclosporin, stabilizing the intellectual property backdrop, but the biggest current risk remains Aurinia’s dependence on a single commercial product despite ongoing litigation with other generic challengers.
In that context, the recent launch of the PRESERVE Phase 4 study of LUPKYNIS combinations is particularly relevant. While the Teva agreement shores up patent protection on paper, PRESERVE speaks directly to whether LUPKYNIS can deepen its clinical role in lupus nephritis, reinforcing one of the key catalysts for Aurinia’s story: converting strong intellectual property into durable real world adoption.
Yet, against the comfort of a later generic entry date, investors should still be aware that...
Read the full narrative on Aurinia Pharmaceuticals (it's free!)
Aurinia Pharmaceuticals' narrative projects $453.5 million revenue and $169.9 million earnings by 2029.
Uncover how Aurinia Pharmaceuticals' forecasts yield a $18.17 fair value, a 10% upside to its current price.
Exploring Other Perspectives
Compared with the consensus view, the most pessimistic analysts were already bracing for earnings to drop toward about US$63 million by 2029, even as they assumed revenue reaching roughly US$407 million; Teva’s settlement may eventually challenge or support that caution, especially if you worry about Aurinia’s single drug dependence and how quickly any pipeline can broaden the story.
Explore 5 other fair value estimates on Aurinia Pharmaceuticals - why the stock might be worth over 2x more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Aurinia Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Aurinia Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aurinia Pharmaceuticals' overall financial health at a glance.
No Opportunity In Aurinia Pharmaceuticals?
Our top stock finds are flying under the radar-for now. Get in early:
- Find 49 companies with promising cash flow potential yet trading below their fair value.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com